← The feed Many Minded · The brief
MOBILITY · forward · impact 1/5 · 2026-11-16 · Lifespan.io

Serotonin Signaling May Slow Aging-Related Mobility in Mice

Mouse research identifies serotonin pathways that suppress movement in aging, offering potential targets for reducing mobility decline in elderly populations.

University of Aberdeen researchers observed that aging mice show reduced physical activity patterns that closely mirror human aging trajectories. Using hip accelerometers, they found that older mice (12-14 months) exhibit decreased movement compared to younger mice (4-6 months), though the study did not track specific human age groups. Key neural mechanisms include altered firing in dorsal raphe neurons—neurons that regulate serotonin signaling. When researchers administered d-fenfluramine (a serotonin releaser), mice moved less during active periods. Knocking out the 5-HT2C receptor in older mice increased movement distance and speed without affecting food intake. Viral delivery of activated caspase-3 for four weeks also improved mobility and reduced body fat in mice, though this approach is not clinically viable for humans.

The findings suggest serotonin signaling through 5-HT2C receptors suppresses dopamine-driven movement capacity in aging. Targeting this pathway could theoretically reduce healthcare costs for age-related mobility decline by addressing the root neural mechanisms rather than symptoms.

This work moves abundance toward older adults by identifying neural pathways where interventions might lower the burden of mobility-related healthcare. However, human applicability remains unproven, and physical capacity changes require separate validation. Next steps include testing serotonin-targeted therapies in larger animal models and clarifying how neural changes translate to real-world mobility. The source explicitly states findings apply only to mice—human relevance is not established.

Source: Lifespan.io